CL2019003258A1 - Composiciones y compuestos terapéuticos y métodos para utilizarlos. - Google Patents
Composiciones y compuestos terapéuticos y métodos para utilizarlos.Info
- Publication number
- CL2019003258A1 CL2019003258A1 CL2019003258A CL2019003258A CL2019003258A1 CL 2019003258 A1 CL2019003258 A1 CL 2019003258A1 CL 2019003258 A CL2019003258 A CL 2019003258A CL 2019003258 A CL2019003258 A CL 2019003258A CL 2019003258 A1 CL2019003258 A1 CL 2019003258A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- compositions
- therapeutic compounds
- jak
- jak inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
LOS COMPUESTOS Y LAS SALES DE ESTOS QUE SON ÚTILES COMO INHIBIDORES DE JAK CINASA SE DESCRIBEN EN LA PRESENTE. TAMBIÉN SE PROPORCIONAN COMPOSICIONES FARMACÉUTICAS QUE INCLUYEN TAL INHIBIDOR JAK Y UN PORTADOR, ADYUVANTE O VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE, Y MÉTODOS PARA TRATAR O AMINORAR LA GRAVEDAD DE UNA ENFERMEDAD O AFECCIÓN QUE RESPONDE A LA INHIBICIÓN DE UNA ACTIVIDAD DE JANUS CINASA EN UN PACIENTE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017085276 | 2017-05-22 | ||
US201862640865P | 2018-03-09 | 2018-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019003258A1 true CL2019003258A1 (es) | 2020-04-17 |
Family
ID=62386421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019003258A CL2019003258A1 (es) | 2017-05-22 | 2019-11-14 | Composiciones y compuestos terapéuticos y métodos para utilizarlos. |
Country Status (19)
Country | Link |
---|---|
US (3) | US10307426B2 (es) |
EP (1) | EP3630766A1 (es) |
JP (2) | JP7256757B2 (es) |
KR (1) | KR20200010390A (es) |
CN (1) | CN110650959B (es) |
AU (1) | AU2018274577A1 (es) |
BR (1) | BR112019024322A2 (es) |
CA (1) | CA3061236A1 (es) |
CL (1) | CL2019003258A1 (es) |
CO (1) | CO2019010559A2 (es) |
CR (1) | CR20190520A (es) |
MA (1) | MA48942A (es) |
MX (1) | MX2019013308A (es) |
PE (1) | PE20200341A1 (es) |
PH (1) | PH12019502601A1 (es) |
RU (1) | RU2769696C2 (es) |
SG (1) | SG11201909735YA (es) |
TW (1) | TW201902896A (es) |
WO (1) | WO2018215389A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018215389A1 (en) * | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
KR20220024405A (ko) | 2019-06-18 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | Jak 키나제의 피라졸로피리미딘 설폰 억제제 및 그 사용 |
EP3986899A1 (en) * | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8401486A1 (es) | 1981-11-10 | 1983-12-01 | Wellcome Found | Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina. |
US4847256A (en) | 1986-10-16 | 1989-07-11 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5705625A (en) | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
US7070972B1 (en) | 1995-01-13 | 2006-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Janus family kinases and identification of immune modulators |
WO1997002289A1 (en) | 1995-07-06 | 1997-01-23 | Zeneca Limited | Peptide inhibitors of fibronectine |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
US7091020B1 (en) | 1995-12-05 | 2006-08-15 | Incyte Corporation | Human Jak2 kinase |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
FR2791562B1 (fr) | 1999-03-29 | 2004-03-05 | Oreal | Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture |
YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
US6841549B1 (en) | 1999-07-02 | 2005-01-11 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
TR200400105T4 (tr) | 1999-12-10 | 2004-02-23 | Prizer Products Inc. | Pirrolo [2,3-d] pirimidin bileşikleri |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
ES2271365T3 (es) | 2001-12-20 | 2007-04-16 | Bayer Healthcare Ag | Derivados de 1,4-dihidro-1,4-difenilpiridina. |
WO2003091256A1 (fr) | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
CA2502429A1 (en) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
JP2006522750A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法 |
WO2004089415A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
US20070270408A1 (en) | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
EP1643960A2 (en) | 2003-07-02 | 2006-04-12 | Merck & Co., Inc. | Arylsulfonamide derivatives |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
US20060030536A1 (en) | 2004-04-09 | 2006-02-09 | University Of South Florida | Combination therapies for cancer and proliferative angiopathies |
US7517888B2 (en) | 2004-04-28 | 2009-04-14 | Cv Therapeutics, Inc. | A1 adenosine receptor antagonists |
US20050288502A1 (en) | 2004-06-25 | 2005-12-29 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
RU2417996C2 (ru) | 2004-11-04 | 2011-05-10 | Вертекс Фармасьютикалз Инкорпорейтед | ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
WO2007039797A1 (en) | 2005-10-03 | 2007-04-12 | Pfizer Products Inc. | Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis |
AR056206A1 (es) * | 2005-10-06 | 2007-09-26 | Schering Corp | Pirazolpirimidinas como inhibidores de protein quinasas |
CN101316847A (zh) | 2005-10-06 | 2008-12-03 | 先灵公司 | 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物 |
CA2626742A1 (en) | 2005-10-21 | 2007-04-26 | Exelixis, Inc. | Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators |
KR20080074161A (ko) | 2005-12-08 | 2008-08-12 | 노파르티스 아게 | EPHB 및 VEGFR2 키나아제 억제제로서의피라졸로[1,5-a]피리딘-3-카르복실산 |
US8541406B2 (en) | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
KR20090075714A (ko) | 2006-10-30 | 2009-07-08 | 노파르티스 아게 | 소염제로서의 헤테로시클릭 화합물 |
CA2670083A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
SI2212297T1 (sl) | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | Inhibitorji protein kinaz |
BRPI0819453A2 (pt) | 2007-11-28 | 2014-10-07 | Dana Farber Cancer Inst Inc | Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
CA2727036C (en) | 2008-06-20 | 2017-03-21 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
US8252791B2 (en) | 2008-08-13 | 2012-08-28 | Jenrin Discovery, Inc. | Purine compounds as cannabinoid receptor blockers |
MX2011004494A (es) | 2008-10-31 | 2011-05-24 | Genentech Inc | Compuestos de pirazolopirimidina inhibidores de jak y metodos. |
WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
US8946426B2 (en) | 2009-02-06 | 2015-02-03 | Janssen Pharmaceuticals, Inc. | Substituted bicyclic heterocyclic compounds as gamma secretase modulators |
TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
KR20120102601A (ko) | 2009-10-20 | 2012-09-18 | 셀좀 리미티드 | Jak 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체 |
CA2793024A1 (en) | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
KR20130094693A (ko) | 2010-04-30 | 2013-08-26 | 셀좀 리미티드 | Jak 저해제로서의 피라졸 화합물 |
MX358682B (es) | 2010-07-13 | 2018-08-31 | Hoffmann La Roche | Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). |
WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
WO2012129258A1 (en) | 2011-03-22 | 2012-09-27 | Merck Sharp & Dohme Corp. | Amidopyrazole inhibitors of interleukin receptor-associated kinases |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
EP2892899B1 (en) | 2012-09-06 | 2018-03-21 | Bristol-Myers Squibb Company | Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
RS59690B1 (sr) | 2012-11-09 | 2020-01-31 | Medicines For Malaria Venture Mmv | Derivativi heteroarila i njihova upotreba |
WO2015006181A1 (en) | 2013-07-11 | 2015-01-15 | Merck Sharp & Dohme Corp. | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) |
ES2777123T3 (es) | 2013-11-08 | 2020-08-03 | Takeda Pharmaceuticals Co | Pirazol para el tratamiento de trastornos autoinmunes |
WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
SG11201609830RA (en) | 2014-05-23 | 2016-12-29 | Hoffmann La Roche | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors |
CN106659787A (zh) | 2014-05-23 | 2017-05-10 | 辉宝动物保健公司 | 组合、组合物及向动物施用所述组合或组合物的方法 |
CN115925711A (zh) | 2014-11-06 | 2023-04-07 | Bial研发投资股份有限公司 | 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途 |
US10040798B2 (en) | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of IRAK4 activity |
WO2016144844A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of irak4 activity |
US10329294B2 (en) | 2015-03-12 | 2019-06-25 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of IRAK4 activity |
WO2016144848A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrrolotriazine inhibitors of irak4 activity |
TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
JP6936236B2 (ja) | 2016-02-18 | 2021-09-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 治療化合物、組成物及びその方法の使用 |
MX2019007339A (es) | 2016-12-29 | 2019-09-06 | Hoffmann La Roche | Compuestos de pirazolopirimidina y metodos de uso de los mismos. |
WO2018166993A2 (en) | 2017-03-14 | 2018-09-20 | F. Hoffmann-La Roche Ag | Pyrazolochlorophenyl compounds, compositions and methods of use thereof |
WO2018215389A1 (en) * | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
TW201900648A (zh) | 2017-05-22 | 2019-01-01 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及組成物以及其使用方法 |
-
2018
- 2018-05-21 WO PCT/EP2018/063262 patent/WO2018215389A1/en active Application Filing
- 2018-05-21 MA MA048942A patent/MA48942A/fr unknown
- 2018-05-21 CA CA3061236A patent/CA3061236A1/en active Pending
- 2018-05-21 JP JP2019564544A patent/JP7256757B2/ja active Active
- 2018-05-21 US US15/984,747 patent/US10307426B2/en active Active
- 2018-05-21 BR BR112019024322-4A patent/BR112019024322A2/pt not_active Application Discontinuation
- 2018-05-21 KR KR1020197037532A patent/KR20200010390A/ko unknown
- 2018-05-21 PE PE2019001932A patent/PE20200341A1/es unknown
- 2018-05-21 AU AU2018274577A patent/AU2018274577A1/en not_active Abandoned
- 2018-05-21 TW TW107117163A patent/TW201902896A/zh unknown
- 2018-05-21 RU RU2019141734A patent/RU2769696C2/ru active
- 2018-05-21 CR CR20190520A patent/CR20190520A/es unknown
- 2018-05-21 CN CN201880033741.6A patent/CN110650959B/zh active Active
- 2018-05-21 MX MX2019013308A patent/MX2019013308A/es unknown
- 2018-05-21 EP EP18727747.0A patent/EP3630766A1/en active Pending
- 2018-05-21 SG SG11201909735Y patent/SG11201909735YA/en unknown
-
2019
- 2019-04-17 US US16/387,187 patent/US20190240227A1/en not_active Abandoned
- 2019-09-27 CO CONC2019/0010559A patent/CO2019010559A2/es unknown
- 2019-11-14 CL CL2019003258A patent/CL2019003258A1/es unknown
- 2019-11-20 PH PH12019502601A patent/PH12019502601A1/en unknown
-
2020
- 2020-07-28 US US16/940,542 patent/US20200352951A1/en not_active Abandoned
-
2023
- 2023-02-14 JP JP2023020805A patent/JP2023058657A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US10307426B2 (en) | 2019-06-04 |
EP3630766A1 (en) | 2020-04-08 |
US20190240227A1 (en) | 2019-08-08 |
SG11201909735YA (en) | 2019-11-28 |
AU2018274577A1 (en) | 2019-10-10 |
CN110650959A (zh) | 2020-01-03 |
MA48942A (fr) | 2020-04-08 |
TW201902896A (zh) | 2019-01-16 |
CO2019010559A2 (es) | 2019-10-09 |
JP2020520959A (ja) | 2020-07-16 |
BR112019024322A2 (pt) | 2020-06-16 |
JP7256757B2 (ja) | 2023-04-12 |
CR20190520A (es) | 2020-01-21 |
WO2018215389A1 (en) | 2018-11-29 |
KR20200010390A (ko) | 2020-01-30 |
RU2019141734A (ru) | 2021-06-23 |
PH12019502601A1 (en) | 2020-06-08 |
US20180333416A1 (en) | 2018-11-22 |
CA3061236A1 (en) | 2018-11-29 |
CN110650959B (zh) | 2023-04-18 |
RU2019141734A3 (es) | 2021-08-10 |
RU2769696C2 (ru) | 2022-04-05 |
JP2023058657A (ja) | 2023-04-25 |
PE20200341A1 (es) | 2020-02-14 |
MX2019013308A (es) | 2020-02-12 |
US20200352951A1 (en) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003258A1 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos. | |
CO2019011809A2 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
ECSP21008112A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
MX2020004283A (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
CO2017000399A2 (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
UY37028A (es) | Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds | |
CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
UY37205A (es) | Inhibidores de bromodominios | |
CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
AR113803A1 (es) | Compuesto de pirimidina como inhibidor de jak quinasas | |
CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 |